Press release
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage
About this update from Maze Therapeutics, Inc.
[{"type":"text","content":"Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotech\nSOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. “I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics,” said Mr. Hoppenot. “With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of MZE829 targeting APOL1-mediated kidney disease, Maze is well-positioned to deliver meaningful progress. The team has consistently demonstrated strong execution, and I look forward to working with them to advance therapies that can transform the lives of patients with kidney and metabolic diseases.” Mr. Hoppenot brings over three decades of experience in therapeutic development and commercial leadership to the Board. He most recently served as Chief Executive Officer of Incyte Corporation from 2014 to 2025 and as Chairman of Incyte from 2015 to 2025, following his appointment to the Board of Directors in 2014. Prior to Incyte, he held senior positions at Novartis, including President of Novartis Oncology, Chief Commercial Officer, and Head of Global Product Strategy & Scientific Development, as well as Senior Vice President and Head of Global Marketing for Novartis Oncology. Earlier in his career, Mr. Hoppenot advanced through a series of leadership roles at Aventis (formerly Rhône-Poulenc), including Vice President of U.S. Oncology. He currently serves on the boards of Incyte, Laboratoires Pierre Fabre, N-Power Medicine and Bicycle Therapeutics, and holds a degree from ESSEC Business School in France. “Hervé is a proven company builder, having transformed Incyte from a single-product company into a diversified biotech leader and driving its growth from $350 million to more than $4 billion in revenue as CEO,” said Jason Coloma, Ph.D., chief executive officer of Maze. “We are honored to ...